The Folliculin-FNIP1 Pathway Deleted in Human Birt-Hogg-Dubé Syndrome is Required for Murine B-cell Development
Overview
Authors
Affiliations
Birt-Hogg-Dubé (BHD) syndrome is an autosomal dominant disorder characterized by cutaneous fibrofolliculomas, pulmonary cysts, and kidney malignancies. Affected individuals carry germ line mutations in folliculin (FLCN), a tumor suppressor gene that becomes biallelically inactivated in kidney tumors by second-hit mutations. Similar to other factors implicated in kidney cancer, FLCN has been shown to modulate activation of mammalian target of rapamycin (mTOR). However, its precise in vivo function is largely unknown because germ line deletion of Flcn results in early embryonic lethality in animal models. Here, we describe mice deficient in the newly characterized folliculin-interacting protein 1 (Fnip1). In contrast to Flcn, Fnip1(-/-) mice develop normally, are not susceptible to kidney neoplasia, but display a striking pro-B cell block that is entirely independent of mTOR activity. We show that this developmental arrest results from rapid caspase-induced pre-B cell death, and that a Bcl2 transgene reconstitutes mature B-cell populations, respectively. We also demonstrate that conditional deletion of Flcn recapitulates the pro-B cell arrest of Fnip1(-/-) mice. Our studies thus demonstrate that the FLCN-FNIP complex deregulated in BHD syndrome is absolutely required for B-cell differentiation, and that it functions through both mTOR-dependent and independent pathways.
Sun Z, Yang L, Kiram A, Yang J, Yang Z, Xiao L Nat Commun. 2023; 14(1):7136.
PMID: 37932296 PMC: 10628247. DOI: 10.1038/s41467-023-42690-9.
Impact of Co-chaperones and Posttranslational Modifications Toward Hsp90 Drug Sensitivity.
Backe S, Woodford M, Ahanin E, Sager R, Bourboulia D, Mollapour M Subcell Biochem. 2022; 101:319-350.
PMID: 36520312 PMC: 10077965. DOI: 10.1007/978-3-031-14740-1_11.
Emerging Link between Tsc1 and FNIP Co-Chaperones of Hsp90 and Cancer.
Backe S, Sager R, Meluni K, Woodford M, Bourboulia D, Mollapour M Biomolecules. 2022; 12(7).
PMID: 35883484 PMC: 9312812. DOI: 10.3390/biom12070928.
Yin Y, Xu D, Mao Y, Xiao L, Sun Z, Liu J J Exp Med. 2022; 219(5).
PMID: 35412553 PMC: 9008465. DOI: 10.1084/jem.20212491.
Seventh BHD international symposium: recent scientific and clinical advancement.
Woodford M, Andreou A, Baba M, van de Beek I, Di Malta C, Glykofridis I Oncotarget. 2022; 13:173-181.
PMID: 35070081 PMC: 8780807. DOI: 10.18632/oncotarget.28176.